ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION BY MARKOV’S MODELING
Abstract
Aim. To evaluate the economic effectiveness of the combined two-drug antihypertensive therapy in patients with arterial hypertension (HT) and high cardiovascular risk by Markov’s modeling.
Material and methods. Patients (n= 65; 19 males and 46 females) with essential HT accompanied by metabolic disorders, history of previous ineffective antihypertensive therapy were included into the study. Patients were randomized into 2 groups. Group V/A was treated with valsartan and amlodipine in fixed-dose combinations of 160/5 and 160/10 mg depending on blood pressure (BP) level. Patients of group L/A were treated with losartan 100 mg and amlodipine 5 or 10 mg daily. Treatment duration was 24 weeks. Changes in BP level, and left ventricular hypertrophy (LVH) regression were assessed. Economic evaluation was performed on the basis of modeling with specialized software Decision Tree 4.xla.
Results. Effect of the two variants of combination therapy on LVH was used to estimate treatment effectiveness and to build the model. Patients were distributed according to the left ventricular mass (LVM) at baseline and after 24 weeks of therapy. Significant decrease in LVM was observed in V/A group: from 225.1±71.7 to 186.3±44.5 g (p<0.05). There was no LVM dynamics in L/A group. The model took into account economic and frequency factors for 10 years forecast. V/A therapy is able to prevent 94 deaths, 22 strokes, and 64 myocardial infarction per 1000 patients. Absence of need in treatment of these prevented events can save about 5.5 million RUR for every 1000 patients. It would reduce the total costs per patient during 10 years. V/A therapy is able to save maximal number of quality adjusted life years (QALY) due to LVM regression (5.016 years). L/A combination is the most economical variant of pharmacotherapy due to low cost of treatment (16.491.25 RUR per 1 QALY). It would take 286.698.7 RUR additionally for one additional QALY in the treatment with V/A, and it is economically effective.
Conclusion. Treatment with V/A fixed-dose combinations shows higher antihypertensive and cardioprotective efficacy in comparison with that in L/A combination therapy. It reduces a risk of acute myocardial infarction, stroke and death more effectively. V/A therapy gains the maximal number of life years and QALY due to LVM regression.
L/A combination is the most cost-effective in terms of cost of life year gained and QALY. L/A combination allows to save costs due to lower cost of treatment.
About the Authors
N. S. Maksimchuk-Kolobova
Kirov State Medical Academy, Kirov
Russian Federation
Russian Federation
E. I. Tarlovskaya
Kirov State Medical Academy, Kirov
Russian Federation
Russian Federation
S. V. Malchikova
Kirov State Medical Academy, Kirov
Russian Federation
Russian Federation
References
1. Gilyarevsky SR. Clinical efficacy and cost-effectiveness of combined fixed-dose angiotensin-converting enzyme inhibitor and thiazide diuretic. Farmateka 2005; (10): 27-35. Russian (Гиляревский С.Р. Клиническая эффективность и экономическая целесообразность применения комбинированных препаратов с фиксированными дозами ингибитора ангиотензинпревращающего фермета и тиазидного диуретика. Фарматека 2005; (10): 27-35).
2. Ostroumova OD, Nedogoda SV Mamaev VI, Shorikova EG. Pharmacoeconomic aspects of efficiency angiotenziprevraschayuschego enzyme inhibitors in hypertension and heart failure. Russian Journal of Medicine 2003; 11 (5): 262-266. Russian (Остроумова О.Д., Недогода С.В., Мамаев В.И., Шорикова Е.Г. Фармакоэкономические аспекты эффективности ингибиторов ангиотензипревращающего фермента при артериальной гипертонии и сердечной недостаточности. Русский Медицинский Журнал 2003;11(5): 262-266).
3. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: b1665.
4. Leonova, MV Erofeev SB, Bykov AV, Belousov YuB. Pharmacoeconomic analysis of antihypertensive treatment: the advantages of fixed combinations. Cardiology 2008; (1): 43-50. Russian (Леонова М.В., Ерофеева С.Б., Быков А.В., Белоусов Ю.Б. Фармакоэкономический анализ антигипертензивной терапии: преимущества фиксированных комбинаций. Кардиология 2008; (1): 43-50).
5. Roth M., Davenport R. Economics sense appreciation of hypertension treatment. Am J Managed Care 1999;4(9):1-8.
6. Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 2005; 170: 407 - 442.
7. Elisaf M, Liberopoulos E.N. Are the pleiotropic effects of drugs used for the prevention of cardiovascular disease clinically relevant? Curr Pharm Des 2009;15(5): 463-466.
8. Koren M.J., Savaage D.D., Casale P.N. Changes in left ventricular mass predict risk in essential hypertension. Circulation 1990;82 (Suppl 11):29.
9. Yurenev A.P. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: Multicentral trial. Am J Hypertens 1992; 5:182-189.
10. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham study. Am J Hyper 2000; 13: S3-S10.
11. Muiesan M.L., Salvetti M., Rizzoni D. et al. Association of change in left ventricular mass with prognosis during longterm antihypertensive treatment. Hypertens 1995; 13: 1091-1097.
12. Kobalava JD, Kotovskaya YuV. Arterial hypertension and atherosclerosis: the main results of the study ELSA. Heart 2002, 3 (1): 6. Russian (Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония и атеросклероз: основные результаты исследования ELSA. Сердце 2002;3(1): 6).
13. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
14. Hoogwerf BJ, Young JB. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.
15. Cleve Clin J Med 2000;67(4): 287-93.
16. Vorobiev PA, editor. Clinical and economic analysis. Moscow: Nyudiamed; 2008. Russian (Воробьев П.А., редактор. Клинико-экономический анализ. М.: Ньюдиамед; 2008).
17. Shepard D.S., Hodgkin D. Cost effectiveness of intensive treatment of hypertension (based on presentations). Am J Manag Care 1998;4 ( Slippl 12): S765-769.
18. Plavinsky SL The theory of decision-making in the clinic: a training manual. St. Petersburg.: StPMAPS; 2001. Russian (Плавинский С.Л. Теория принятия решений в клинике: учебное пособие. СПб.: СПбМАПО; 2001).
19. Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation 1998; 97: 1837–1847.
20. Koren M.J., Savaage D.D., Casale P.N. Changes in left ventricular mass predict risk in essential hypertension. Circulation 1990;82 (Suppl 11): 29.
21. Balahonova TV, Chazova IE, Saidov MA, et al. The features of target organ damage in hypertensive patients with the presence and absence of metabolic syndrome. Ter Arkhiv 2009, (6):67-73. Russian (Балахонова Т.В., Чазова И.Е., Саидова М.А., и др. Особенности поражения органов-мишеней у больных артериальной гипертонией с наличием и в отсутствие метаболического синдрома. Терапевтический Архив 2009; (6):67-73).
22. Karpov YuA., Chazova IE, Vigdorchik AV. The efficacy and safety of a fixed combination of amlodipine and valsartan in the treatment of hypertension in clinical practice: results of observational studies of the Russian EXTRA-2. System Hypertension 2010 (4): 14-21. Russian (Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные Гипертензии 2010; (4): 14–21).
23. Klingbeil A. U. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
24. Rudakova A.V. Pharmacoeconomic analysis of the organization of centralized drug supply. Pharmindex Practic 2004; (6) :47-52. Russian (Рудакова А.В. Фармакоэкономический анализ в организации централизованного лекарственного обеспечения. Фарминдекс-Практик 2004;(6):47-52).
25. WHO. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization; 2001.
26. Yagudina RI, Kulikov AU, Litvinenko MM QALY: history, methodology and the future of the method. Pharmacoeconomics 2010; (1):7-11. Russian (Ягудина Р.И., Куликов А.Ю., Литвиненко М.М. QALY: история, методология и будущее метода. Фармакоэкономика 2010;(1):7-11).
Review
For citations:
Maksimchuk-Kolobova N.S., Tarlovskaya E.I., Malchikova S.V. ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION BY MARKOV’S MODELING. Rational Pharmacotherapy in Cardiology. 2013;9(3):251-257. (In Russ.)
Views: 1063
Email this article 